Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-15.28M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 22.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 132.07 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -23.58% |
| Return on Assets (Trailing 12 Months) | -20.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.19 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 83.99M |
| Free Float | 57.70M |
| Market Capitalization | $1.41B |
| Average Volume (Last 20 Days) | 0.97M |
| Beta (Past 60 Months) | 0.97 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 46.64% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |